Innovation Across Borders: Strategies for U.S. and Chinese Companies in the Health Sciences Industry

January 8, 2019 | San Francisco, CA | Duane Morris LLP

Duane Morris and the Chinese Biopharmaceutical Association (USA) will host panel discussions about cross-border deals between the U.S. and China on January 8, 2019, from 7:30 a.m. to 11:00 a.m. at Duane Morris' San Francisco office.

Duane Morris LLP
Spear Tower | One Market Plaza, Suite 2200
San Francisco, CA 94105-1127

Breakfast and Registration: 7:30 a.m. to 8:00 a.m.
Welcome and Introduction: 8:00 a.m. to 8:15 a.m.
Panels and Company Presentations: 8:15 a.m. to 11:00 a.m.

REGISTER by January 3

About the Program

Duane Morris and the Chinese Biopharmaceutical Association (USA) invite you to a breakfast and panel discussion from industry and legal professionals with real-world experience handling cross-border deals between the U.S. and China. The panel will discuss issues related to investment in life sciences companies headquartered in the United States and China; the practical challenges of a Chinese life sciences company bringing products to the United States and a U.S. company looking to locate some of its business in China; IP issues in China and the U.S.; trade issues; and other issues involved in cross-border pharmaceutical, biotech and device transactions, commercial arrangements, manufacturing and distribution.


Welcome Remarks and Introduction

  • Dr. Kening Li, Director, Duane Morris & Selvam LLP; Partner, Duane Morris LLP
  • Jonathan Lourie, Partner, Duane Morris LLP

U.S. and China Life Sciences: Cross-Border Transactions and Commercial Arrangements


  • Dr. Guo-Liang Yu, CEO and Co-Founder of Apollomics Pharmaceuticals Inc., Former Executive Chairman of Crown Bioscience Inc., and Founder and Former CEO of Epitomics, Inc.
  • Patrick Gallagher, Aquilo Partners
  • Joel Ephross, Partner, Duane Morris LLP


  • Sandra Stoneman, Partner, Duane Morris LLP

Navigating a Pharmaceutical Products Recall in the United States


  • Alan Klein, Partner, Duane Morris LLP
  • Robert A. Rhoades, Managing Partner, Validant


Life Sciences Technology in China – Company Presentations

Duane Morris and CBA are pleased to provide early stage companies the opportunity to present their investment proposals and plans.

Companies Seeking Investment from the United States

  • Dr. Hardy Chan, Chairman and President, Allianz Pharmascience
  • Dr. Grace Yeh, CEO and President, PharmaEngine, Inc.

Companies Seeking Investment from China

  • James Egan, President and CEO, TargaGenix, Inc.
  • Nicolas Sitchon, President and CEO, S1 Biopharma, Inc.


  • Dr. Patrick Gallagher, Partner, Duane Morris LLP
  • Dr. Kening Li, Director, Duane Morris & Selvam LLP; Partner, Duane Morris LLP